AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03758846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Therapy for Stroke
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists.
Study NCT03758846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Therapy for Older adults
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists.
Study NCT03758846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home education for Older adults
Description: Participants will receive a one-hour education on conventional physical exercises.
Study NCT01890031 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interactive Cholesterol Advisory Tool
Description: using the virtual clinician computer program for cholesterol information and education.
Study NCT01890031 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study physician visits
Description: In-person individual visits with a study physician to give information on cholesterol
Study NCT04021745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based mindful eating
Description: This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
Study NCT02578251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT02578251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Study NCT03749239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen protein
Description: Collagen protein
Study NCT04586257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
Study NCT04586257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Throacolumbar interfacial plane block
Description: USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
Study NCT00480727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Halo pin re-tensioning
Description: Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
Study NCT00480727 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Re-tensioning
Description: Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
Study NCT00829244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL f® prefilled pen
Description: GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
Study NCT00829244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GONAL f® prefilled pen
Description: GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
Study NCT00877656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: Active treatment
Study NCT00894881 — intervention group
Intervention type: PROCEDURE
Intervention: Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]
Description: resting energy expenditure (REE).
Study NCT04559724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Therapy
Description: Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
Study NCT03441048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lintuzumab-Ac-225
Description: Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
Study NCT02135133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg BID Oral Daily
Study NCT02135133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
Study NCT00496119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: 70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
Study NCT00496119 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Therapy
Description: Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
Study NCT06192550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound Matrix™ System
Description: Study subjects will be treated with the Profound Matrix System
Study NCT04344912 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
Study NCT03441048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine is a purine antimetabolite.
Study NCT03441048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is an antineoplastic anti-metabolite.
Study NCT03441048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone is an anthracenedione antineoplastic agent.
Study NCT02166463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04278781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
Study NCT02574715 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Jaydess, BAY86-5028)
Description: Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
Study NCT02172196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study NCT02172196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT01767610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized fenofibrate 160mg
Study NCT03441048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
Study NCT03368001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE Theatre
Description: SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
Study NCT03368001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tackling Teenage Together
Description: The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
Study NCT04074499 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention.
Study NCT04143646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based prevention program
Description: Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk.
Study NCT03425526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Description: Given IV
Study NCT00869570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
Study NCT00869570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Phase II: 1 x 400 mg per day (during 5 weeks)
Study NCT00869570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
Study NCT03030950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
Study NCT03030950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: to give normal saline to the other group as a placebo
Study NCT03514199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet
Description: Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa.
Study NCT03514199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
Study NCT01767610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin Ca 2mg
Study NCT01767610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized fenofibrate 160mg plus pitavastatin Ca 2mg
Study NCT04034836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scalp blocks with ropivacaine plus parecoxib
Description: Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
Study NCT02166463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03474107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Intravenous infusion
Study NCT03474107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Intravenous infusion
Study NCT03474107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinflunine
Description: Intravenous infusion
Study NCT03474107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous infusion
Study NCT02015598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbocysteine
Description: carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
Study NCT02015598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
Study NCT04089605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone implant
Description: intravitreal dexamethasone implant injections in vitrectomized patients with DME
Study NCT04089605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal ranibizumab injections in vitrectomized patients with DME
Study NCT03002116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue thermometry using non-invasive microwave radiometry device
Description: In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
Study NCT03002116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue thermometry using non-invasive microwave radiometry device
Description: In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
Study NCT02711761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheterization
Description: 15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm.
Study NCT02711761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheterization
Description: 15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm.
Study NCT02531035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin, once daily, before the first meal of the day
Study NCT02531035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day
Study NCT00754052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept (donepezil hydrochloride)
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
Study NCT00754052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept (donepezil hydrochloride)
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
Study NCT00754052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
Study NCT03760016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Aerobic Training
Description: Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
Study NCT03760016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
Study NCT03090490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment discontinuation
Description: Withdrawal of antipsychotic medication to stabilized patients
Study NCT03090490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance treatment discontinuation
Description: Maintenance antipsychotic medication to stabilized patients
Study NCT01374724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Use Ban
Description: Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
Study NCT01374724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Pamphlet
Description: A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.